MarginsXMarginsX
Home › Markets › Health Care › RVMD

Revolution Medicines Inc. (RVMD)

RVMD trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$166.87
-3.15% on the day
Market cap
$36.1B
Large cap
Revenue · 2025
$0
Prior year not contiguous
Net income · 2025
-$1.1B

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1628171/000119312526071563/0001193125-26-071563-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerRVMD on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2020
SEC CIK0001628171
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$0
Net income-$1.1B
Operating income-$1.2B
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growthNo prior-year revenue to compare
Cash$383.7M
Total assets$2.4B
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
5.2 months
$615.9M cash at September 30, 2026
Share count, 1 year
+11.9%
2025-10-31 to 2026-10-30 · +97.4% over 3 years
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
-$155.2M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-04
Cash and burn$615.9M cash; operating cash flow -$357.8M a quarter.Report 2026-09-30
Shares outstanding216,292,323 (2026-10-30); 193,319,805 a year earlier; 109,564,695 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 5 424B5 takedowns, 5 at the marketLatest 2026-04-15
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, San Jose, California, United StatesPCAOB Form AP 2026-03-09
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $155.2M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$197.6M-$407.5M-$415.6M$615.9MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q2 2026
2026-06-30
Not filed-$644.4M-$387.3M$815.4MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q1 2026
2026-03-31
Not filed-$453.8M-$354.2M$440.9MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q4 2025
2025-12-31
$0-$364.9M-$274.2M$383.7MNo debt tags$010-K 2026-02-25
Q3 2025
2025-09-30
$0-$305.2M-$207.3M$217.4MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q2 2025
2025-06-30
Not filed-$247.8M-$221.8M$402.4MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q1 2025
2025-03-31
Not filed-$213.4M-$194.4M$333.6MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q4 2024
2024-12-31
$0-$194.6M-$138.3M$543.1MNo debt tags$010-K 2026-02-25

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-04-15
Latest annual report10-K2026-02-25
Latest quarterly / interim10-Q2026-11-04
Latest current report8-K2026-11-04
Latest proxyDEFA14A2026-04-28

Source: SEC EDGAR submissions feed, 870 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-10.4%
1 month-8.6%
3 months-14.7%
Year to date+116.3%
1 year+167.6%
From 52-week high-22.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Other listings for this company

TickerNamePrice
RVMDWRevolution Medicines Inc. Warrant$7.12

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
BIIBBiogen Inc.$251.65-0.69%$37.2B
ARGXargenx SE$950.95-0.95%$59.0B
BNTXBioNTech SE American Depositary Share$85.26-0.40%$21.4B
NBIXNeurocrine Biosciences Inc.$165.31-1.25%$16.7B
EXELExelixis Inc.$67.10-2.75%$16.4B
MRNAModerna Inc.$215.27-3.63%$87.1B
TECHBio-Techne Corp$72.79-0.01%$11.4B
HALOHalozyme Therapeutics Inc.$96.50-3.76%$11.0B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier